Seek Returns logo

ABBV vs. CYTK: A Head-to-Head Stock Comparison

Updated

Here’s a clear look at ABBV and CYTK, comparing key factors like performance, valuation metrics, dividends, and financial strength. It’s built for investors or anyone curious to see how these two stocks match up.

Company Overview

ABBV dominates in value with a market cap of 321.13 billion USD, eclipsing CYTK’s 3.69 billion USD by roughly 87.10×.

With betas of 0.55 for ABBV and 0.81 for CYTK, both show similar volatility profiles relative to the overall market.

SymbolABBVCYTK
Company NameAbbVie Inc.Cytokinetics, Incorporated
CountryUSUS
SectorHealthcareHealthcare
IndustryDrug Manufacturers - GeneralBiotechnology
CEOMr. Robert A. Michael CPAMr. Robert I. Blum
Price181.8 USD30.873 USD
Market Cap321.13 billion USD3.69 billion USD
Beta0.550.81
ExchangeNYSENASDAQ
IPO DateJanuary 2, 2013April 30, 2004
ADRNoNo

Performance Comparison

This chart compares the performance of ABBV and CYTK over the past year by tracking the growth of an initial $10,000 investment in each (starting one year ago).

Hover over the lines to see the investment’s value and total return (%) at specific dates.

Data is adjusted for dividends and splits.

Valuation Metrics Comparison

The section examines key financial ratios to assess the valuation of ABBV and CYTK based on earnings, cash flow, sales, and book value. Pay attention to the following notable points where extreme values stand out.

  • CYTK shows a negative P/E of -5.95, highlighting a year of losses, whereas ABBV at 76.62 trades on solid profitability.
  • CYTK carries a sub-zero price-to-book ratio of -13.73, indicating negative equity. In contrast, ABBV (P/B 226.35) has positive book value.
  • CYTK reports a negative Price-to-Free Cash Flow ratio of -9.01, showing a cash flow shortfall that could threaten its operational sustainability, while ABBV at 20.87 maintains positive cash flow.
SymbolABBVCYTK
Price-to-Earnings Ratio (P/E, TTM)76.62-5.95
Forward PEG Ratio (TTM)7.1610.43
Price-to-Sales Ratio (P/S, TTM)5.60191.86
Price-to-Book Ratio (P/B, TTM)226.35-13.73
Price-to-Free Cash Flow Ratio (P/FCF, TTM)20.87-9.01
EV-to-EBITDA (TTM)23.58-8.54
EV-to-Sales (TTM)6.73229.18
EV-to-Free Cash Flow (TTM)25.08-10.76

Dividend Comparison

ABBV delivers a 3.51% dividend yield, blending income with growth, whereas CYTK appears to retain its profits, possibly to fund operations, R&D, or other growth initiatives.

SymbolABBVCYTK
Dividend Yield (TTM)3.51%0.00%

Financial Strength Metrics Comparison

This section dives into the financial resilience of ABBV and CYTK, spotlighting key metrics like liquidity, leverage, and debt coverage. Check out the standout observations below where notable differences or extremes pop up.

  • ABBV’s current ratio of 0.76 signals a possible liquidity squeeze, while CYTK at 5.99 comfortably covers its short-term obligations.
  • ABBV’s quick ratio of 0.64 suggests it may struggle to cover immediate liabilities without selling inventory or raising cash, whereas CYTK at 5.99 maintains a comfortable buffer of liquid assets.
  • ABBV carries high leverage (debt-to-equity ratio 49.22), whereas CYTK has negative equity (-2.97), each presenting distinct capital-structure concerns.
  • ABBV meets its interest obligations (ratio 6.14). In stark contrast, CYTK’s negative ratio (-6.14) means its operating earnings (EBIT) don't cover basic operations, let alone interest, signaling serious financial trouble.
SymbolABBVCYTK
Current Ratio (TTM)0.765.99
Quick Ratio (TTM)0.645.99
Debt-to-Equity Ratio (TTM)49.22-2.97
Debt-to-Assets Ratio (TTM)0.510.63
Interest Coverage Ratio (TTM)6.14-6.14